http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#Head
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#assertion
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#provenance
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#pubinfo
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#assertion
http://purl.obolibrary.org/obo/DOID_14332
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_14332
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00915
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association
http://www.w3.org/2000/01/rdf-schema#label
amantadine hydrochloride capsules usp are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus amantadine hydrochloride capsules usp are also indicated in the treatment of parkinsonism and drug induced extrapyramidal reactions influenza a prophylaxis amantadine hydrochloride capsules usp are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection because amantadine hydrochloride does not completely prevent the host immune response to influenza a infection individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses following vaccination during an influenza a outbreak amantadine hydrochloride capsules usp prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response influenza a treatment amantadine hydrochloride capsules usp are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza a virus strains especially when administered early in the course of illness there are no well controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules usp will avoid the development of influenza a virus pneumonitis or other complications in high risk patients there is no clinical evidence indicating that amantadine hydrochloride capsules usp are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza a virus strains the following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules usp amantadine hydrochloride capsules usp is not a substitute for early vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices influenza viruses change over time emergence of resistance mutations could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride capsules usp parkinson s disease syndrome amantadine hydrochloride capsules usp are indicated in the treatment of idiopathic parkinson s disease paralysis agitans postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication it is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis in the treatment of parkinson s disease amantadine hydrochloride capsules usp are less effective than levodopa 3 3 4 dihydroxyphenyl l alanine and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established drug induced extrapyramidal reactions amantadine hydrochloride capsules usp are indicated in the treatment of drug induced extrapyramidal reactions although anticholinergic type side effects have been noted with amantadine hydrochloride capsules usp when used in patients with drug induced extrapyramidal reactions there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00915
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#provenance
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#pubinfo
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#sig
http://purl.org/nanopub/x/hasSignature
YXqetJJHFIc3Qz4mGng51yuErSYyJisI5zkzRjtLzXt2jpvMa4mf7KUjNj+uAAJ9hMsG0dpcND5KD4Rf2rtc/uPlhlMkgQh4MNgkDHL4nZepuSh4gZqBGrgm1MUwXED9fWFxhnJ8+jxtX5fbO/DHuvkJvCliKy8gdMnaU6tr504=
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q
http://purl.org/dc/terms/created
2021-06-21T09:58:16.891+02:00
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs